8. Saving Lives by Anticipating Actions: Getting it right on Screening and Early Detection

Gavin Lewis is Amgen’s VP Global Value and Access based at the company’s European Hub in... Gavin Lewis is Amgen’s VP Global Value and Access based at the company’s European Hub in Switzerland. Founded in California in 1980, Amgen is a global leader in biotechnology. Gavin originally was an undergraduate in Economics and Politics, before working for the Scottish Government as an Economist in the Health Department. After obtaining an MSc in Health Economics from York University, he joined the Pharmaceutical industry for Roche in the UK where he worked for over 10 years developing and leading their Health Economics and Pricing department. He has experience in leading over 50 Health Technology appraisals and contributed to the development of the NICE Guide to Methods for Technology Appraisal. In 2012 Gavin transferred to Basel to start a new role for Roche as Head of Pricing and Market Access for Region Europe, where he has developed a new team with responsibilities for strategic pricing, payer marketing and real world evidence for Europe. Gavin was then Global Head of Market Access for Oncology at AstraZeneca from 2015-17, before joining Amgen. Read more Show less

Jan van Meerbeeck is Board Member, European Cancer Organisation and Prevention Network Co-Chair.... Jan van Meerbeeck is Board Member, European Cancer Organisation and Prevention Network Co-Chair. After obtaining his medical degree magna cum laude from the University of Antwerp in 1980, Prof van Meerbeeck completed training to become a board certified specialist in internal medicine and pulmonology. He is a skilled interventional pulmonologist and obtained his PhD in 1997 with a dissertation on the presentation of lung cancer in Flanders, Belgium. He is currently professor of Thoracic Oncology at both Ghent and Antwerp University and practiced as pulmonologist at Antwerp University Hospital, Belgium and at Erasmus MC, the Netherlands. He was Chair of the Thoracic Oncology Program at Ghent University Hospital, where he became also Divisional Head and CMO. He is currently appointed full professor in Pulmonology @ Antwerp University and chair of the Pulmonology Department of its academic hospital (UZA). His translational scientific interests include the molecular diagnosis of lung cancer, the management of mesothelioma and the evaluation of volatile biomarkers of asbestos exposure. He is or was the study coordinator or Principal Investigator for numerous international phase 2 and 3 studies in thoracic oncology and respiratory medicine and promoter of several master thesis and PhD students, of which 7 successfully obtained their PhD. Together with Kevin Lamote, he is the founder of the breathomics lab within the Laboratory of experimental medicine and pediatrics (LEMP) @ University of Antwerp. He is furthermore fellow of the European Respiratory Society (ERS) and serves its Thoracic Oncology Assembly as current chair and member of the mesothelioma guideline committee. He served the Lung Cancer Group of the EORTC as secretary, chairman and as board member, is a full member of the ASCO and the IASLC (current member of its staging committee), and expert at the Belgian HTA Knowledge Center KCE. He was involved in the development of the ICHOM standard set on Lung cancer and board member of All.Can and All.Can Belgium. He has an extensive presentation and publication track, with more than 300 peer-reviewed articles in various journals and chapters in textbooks. He serves on the review and editorial boards of several international journals, and organized several national and international meetings. Read more Show less